Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Unum Therapeutics to Present on its Antibody-Coupled T-Cell Receptor (ACTR) Platform at the Upcoming 58th American Society of Hematology (ASH) Annual Meeting

Unum Therapeutics Inc.
Posted on: 01 Dec 16

Unum Therapeutics, a clinical stage biopharmaceutical company developing a universal cellular immunotherapy to treat multiple cancers, today announced that the Company has been selected for two poster presentations on its Antibody-Coupled T-cell Receptor (ACTR) platform at the 58th ASH Annual Meeting, which is being held in San Diego, California, December 3-6, 2016.

In addition, Dr. Michelle Poon of the NUH in Singapore, will be presenting initial results of an ongoing Investigator Sponsored Trial using autologous T-cells with ACTR transiently expressed through mRNA electroporation in combination with rituximab in patients with relapsed/refractory CD20+ B-cell Non Hodgkin lymphoma (B-NHL) (ATTCK20; ClinicalTrials.gov No. NCT02315118). Following the initial results of this ongoing trial, Unum recently announced the initiation of a clinical trial for patients with relapsed/refractory CD20+ B-NHL in which ACTR is durably expressed through viral delivery in autologous T-cells (ACTR087; ClinicalTrials.gov No. NCT02776813).

Presentation Details:

Presentation Title: Targeting CD20+ Relapsed Refractory B-Cell Lymphoma with ACTR087, Antibody-Coupled T-Cell Receptor (ACTR) Engineered Autologous T-Cells, in Combination with Rituximab
Presenter: Heather A. Huet, Senior Director of Drug Discovery, Unum Therapeutics
Presentation Date: Sunday, December 4, 2016
Presentation Time: 6:00 p.m.‐8:00 p.m.
Room: Hall GH (San Diego Convention Center)
Session: 801. Gene Therapy and Transfer: Poster II
Abstract Number: 3512

Presentation Title: ACTR Platform as an Adaptable, Universal T-Cell Therapy That Can Target Multiple Tumor Antigens to Overcome Antigen Escape
Presenter: Greg Motz, Senior Scientist, Unum Therapeutics
Presentation Date: Sunday, December 4, 2016
Presentation Time: 6:00 p.m.‐8:00 p.m.
Room: Hall GH (San Diego Convention Center)
Session: 703. Adoptive Immunotherapy: Poster II
Abstract Number: 3362

Presentation Title: A First-in-Human Study of Autologous T Lymphocytes with Antibody-Dependent Cell Cytotoxicity (ADCC) in Patients with B-Cell Non-Hodgkin Lymphoma (NHL)
Presenter: Michelle Poon, MD Senior Consultant, Department of Hematology-Oncology,
National University Cancer Institute, Singapore (NCIS)
Presentation Date: Sunday, December 4, 2016
Presentation Time: 6:00 p.m.‐8:00 p.m.
Room: Hall GH (San Diego Convention Center)
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster II
Abstract Number: 3031

The posters will be posted on Unum’s website following the presentations.

About Antibody-Coupled T-Cell Receptor (ACTR) Technology and ACTR087
Unum’s proprietary ACTR is a chimeric protein that combines components from receptors normally found on two different human immune cell types – natural killer (NK) cells and T-cells – to create a novel cancer cell killing activity. T-cells bearing the ACTR receptor protein can be directed to attack a tumor by combining with a monoclonal antibody that binds antigens on the cancer cell surface.

In contrast to other T-cell therapy approaches for cancer that are limited to a single cancer cell surface target and, therefore, treat a narrow set of tumors, Unum’s approach is not restricted by a specific tumor cell antigen and, thus, may have applications for treating many different types of cancers when combined with the right antibody.

Unum is developing ACTR in combination with a range of tumor-targeting antibodies for use in both hematologic and solid tumor indications. ACTR087, Unum’s most advanced product candidate, combines Unum’s proprietary ACTR, with rituximab, an anti-CD20 antibody. The ACTR087 study will be the first clinical trial using a viral vector to permanently insert the ACTR gene into the genome of patient T-cells.

About Unum Therapeutics
Unum Therapeutics uses its proprietary Antibody-Coupled T-cell Receptor (ACTR) technology in combination with tumor-targeting antibodies, which is designed to activate the body’s own immune system to fight cancer. Unum is actively building a pipeline of ACTR programs in which proprietary, tumor-targeting antibodies are armed to improve their therapeutic potential. The Company is headquartered in Cambridge, MA. For more information, visit www.unumrx.com/.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161204005003/en/

Business Wire
www.businesswire.com

Last updated on: 04/12/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.